Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma

Sabran J. Masoud, Jennifer A. Perone, Norma E. Farrow, Paul J. Mosca, Douglas Tyler, Georgia M. Beasley

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. However, their conclusions are limited by study populations which overall harbored a lower burden of SLN disease. Special attention needs to be given to patients who do have higher risk disease, with SLN tumor burdens exceeding 1 mm in diameter, for whom CLND may remain both prognostic and therapeutic. Current guidelines thus recommend either CLND or careful observation after positive SLNB after appropriate risk stratification of patients. While a decline in CLND is inevitable, treatment of stage III melanoma is witnessing the concurrent rise of effective adjuvant therapies. PD-1 inhibitors such as nivolumab, or combination BRAF/MEK inhibitors for V600E or K mutant melanoma, which were previously available to only trial patients with completely resected stage III disease, are now approved for use in patients with positive SLNB alone. Providers are better equipped than ever to treat clinically occult, regional metastatic disease with SLNB followed by adjuvant therapy for most patients, but should take steps to avoid undertreatment of high-risk patients who may proceed to disease relapse or progression.

Original languageEnglish (US)
Article number55
JournalCurrent Treatment Options in Oncology
Volume19
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Sentinel Lymph Node Biopsy
Lymph Node Excision
Melanoma
Shiga Toxin 2
Observation
Recurrence
Mitogen-Activated Protein Kinase Kinases
Therapeutics
Tumor Burden
Dissection
Guidelines
Neoplasm Metastasis
Survival

Keywords

  • Lymph node dissection
  • Melanoma
  • Metastasis
  • Sentinel lymph node biopsy
  • Staging
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. / Masoud, Sabran J.; Perone, Jennifer A.; Farrow, Norma E.; Mosca, Paul J.; Tyler, Douglas; Beasley, Georgia M.

In: Current Treatment Options in Oncology, Vol. 19, No. 11, 55, 01.11.2018.

Research output: Contribution to journalReview article

Masoud, Sabran J. ; Perone, Jennifer A. ; Farrow, Norma E. ; Mosca, Paul J. ; Tyler, Douglas ; Beasley, Georgia M. / Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma. In: Current Treatment Options in Oncology. 2018 ; Vol. 19, No. 11.
@article{0d7f6654a66144199dd079956ce1e2c6,
title = "Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma",
abstract = "This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. However, their conclusions are limited by study populations which overall harbored a lower burden of SLN disease. Special attention needs to be given to patients who do have higher risk disease, with SLN tumor burdens exceeding 1 mm in diameter, for whom CLND may remain both prognostic and therapeutic. Current guidelines thus recommend either CLND or careful observation after positive SLNB after appropriate risk stratification of patients. While a decline in CLND is inevitable, treatment of stage III melanoma is witnessing the concurrent rise of effective adjuvant therapies. PD-1 inhibitors such as nivolumab, or combination BRAF/MEK inhibitors for V600E or K mutant melanoma, which were previously available to only trial patients with completely resected stage III disease, are now approved for use in patients with positive SLNB alone. Providers are better equipped than ever to treat clinically occult, regional metastatic disease with SLNB followed by adjuvant therapy for most patients, but should take steps to avoid undertreatment of high-risk patients who may proceed to disease relapse or progression.",
keywords = "Lymph node dissection, Melanoma, Metastasis, Sentinel lymph node biopsy, Staging, Survival",
author = "Masoud, {Sabran J.} and Perone, {Jennifer A.} and Farrow, {Norma E.} and Mosca, {Paul J.} and Douglas Tyler and Beasley, {Georgia M.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s11864-018-0575-4",
language = "English (US)",
volume = "19",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma

AU - Masoud, Sabran J.

AU - Perone, Jennifer A.

AU - Farrow, Norma E.

AU - Mosca, Paul J.

AU - Tyler, Douglas

AU - Beasley, Georgia M.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. However, their conclusions are limited by study populations which overall harbored a lower burden of SLN disease. Special attention needs to be given to patients who do have higher risk disease, with SLN tumor burdens exceeding 1 mm in diameter, for whom CLND may remain both prognostic and therapeutic. Current guidelines thus recommend either CLND or careful observation after positive SLNB after appropriate risk stratification of patients. While a decline in CLND is inevitable, treatment of stage III melanoma is witnessing the concurrent rise of effective adjuvant therapies. PD-1 inhibitors such as nivolumab, or combination BRAF/MEK inhibitors for V600E or K mutant melanoma, which were previously available to only trial patients with completely resected stage III disease, are now approved for use in patients with positive SLNB alone. Providers are better equipped than ever to treat clinically occult, regional metastatic disease with SLNB followed by adjuvant therapy for most patients, but should take steps to avoid undertreatment of high-risk patients who may proceed to disease relapse or progression.

AB - This review critically evaluates recent trials which have challenged the practice of completion lymph node dissection (CLND) for melanoma patients diagnosed with regional metastasis by positive sentinel lymph node biopsy (SLNB). Two trials in the last 2 years, DeCOG-SLT and MSLT-II, found no significant differences in melanoma-specific survival between patients, whether they received immediate CLND or observation after positive SLNB, despite decreases in nodal recurrence achieved by dissection. These trials together disfavor routine CLND in most patients after positive SLNB. However, their conclusions are limited by study populations which overall harbored a lower burden of SLN disease. Special attention needs to be given to patients who do have higher risk disease, with SLN tumor burdens exceeding 1 mm in diameter, for whom CLND may remain both prognostic and therapeutic. Current guidelines thus recommend either CLND or careful observation after positive SLNB after appropriate risk stratification of patients. While a decline in CLND is inevitable, treatment of stage III melanoma is witnessing the concurrent rise of effective adjuvant therapies. PD-1 inhibitors such as nivolumab, or combination BRAF/MEK inhibitors for V600E or K mutant melanoma, which were previously available to only trial patients with completely resected stage III disease, are now approved for use in patients with positive SLNB alone. Providers are better equipped than ever to treat clinically occult, regional metastatic disease with SLNB followed by adjuvant therapy for most patients, but should take steps to avoid undertreatment of high-risk patients who may proceed to disease relapse or progression.

KW - Lymph node dissection

KW - Melanoma

KW - Metastasis

KW - Sentinel lymph node biopsy

KW - Staging

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85053513106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053513106&partnerID=8YFLogxK

U2 - 10.1007/s11864-018-0575-4

DO - 10.1007/s11864-018-0575-4

M3 - Review article

VL - 19

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 11

M1 - 55

ER -